Japanese MHLW approves Chugai Pharma Herceptin for additional indication
With this approval, Herceptin is now available for patients with HER2-positive advanced or recurrent gastric cancer and HER2-positive breast cancer (advanced or recurrent / postoperative adjuvant chemotherapy) in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.